RheumaLogics ApS
CVR 45253295 · Private limited company (ApS) · Active · Medium risk
RheumaLogics ApS is a Private limited company (ApS), founded on , based in København Ø. The company is registered in the industry forskning og eksperimentel udvikling inden for naturvidenskab og teknik. Our model estimates a bankruptcy risk of 1.6% over the next 12 months, which is 1.1 times the average for Danish companies. 1 annual report has been published. The latest annual report (31 Dec 2025) shows equity of DKK 22.4m and a net result of DKK -39.7m. CEO: Søren Sylvester Skjærbæk.
Bankruptcy risk for RheumaLogics ApS
1.1 × the average (1.41%) · higher risk than 79% of active Danish companies
Increases the risk
Reduces the risk
The factors show how often companies with the same characteristic went bankrupt compared with the average (“lift”). The risk is a statistical estimate from a model trained on 141,000+ Danish bankruptcies (AUC 0.93) – not a credit rating. Read about the method.
Company details
- CVR number
- 45253295
- Status
- Active
- Company type
- Private limited company (ApS)
- Founded
- (1 years)
- Address
- c/o Symbion, Fruebjergvej 3
2100 København Ø - Municipality
- København
- Industry
- Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721000)
Bankruptcies in the industry: Anden forskning og eksperimentel udvikling inden for naturvidenskab og teknik - Share capital
- DKK 1.1m
- Auditor
- EY Godkendt Revisionspartnerselskab
- Audit opted out
- No
Warning signs
| Annual reports filed late | 0 of 1 |
| Missing annual report | No |
| Negative equity | No |
| Equity ratio | 31.4% |
| Current ratio | 266% |
| Moves (last 2 years) | 1 |
| CEO changes in total | 2 |
| CEO's previous bankruptcies | 0 |
| Other companies at the address | 611 |
| Going-concern uncertainty | No |
Financials and key figures
| Financial year | 2025 |
|---|---|
| Gross profit | DKK -44.6m |
| Net profit | DKK -39.7m |
| Equity | DKK 22.4m |
| Total assets | DKK 71.2m |
| Cash | DKK 31.4m |
| Short-term debt | DKK 16.5m |
| Avg. employees | 1 |
Latest annual report: Reporting class B · auditor's statement: Revisionspåtegning · (venstre underskriver).
Filed annual reports
| Reporting period | Published | Days after period end | |
|---|---|---|---|
| 5 Dec 2024 – 31 Dec 2025 | 176 |
The annual report must reach the Danish Business Authority no later than 5 months after the end of the financial year. We mark reports published more than 6 months after as “late”.
Management, owners and auditor
| Role | Name | From | To |
|---|---|---|---|
| CEO | Søren Sylvester Skjærbæk | Current | |
| CEO | Jørgen Søberg Petersen | ||
| Board | Jørgen Søberg Petersen | Current | |
| Board | Gabor Gyulveszi | Current | |
| Board | Alex Thomas Pasteur | Current | |
| Board | Balaji Muralidhar | Current | |
| Board | Megan Shea Lipcsey | Current | |
| Board | Marianne Uteng | Current | |
| Board | Reinaldo Miguel Diaz | ||
| Owner (33%) | Novo Holdings A/S | Current | |
| Owner (5%) | Demetrios Thomas Braddock | Current | |
| Owner (10%) | F-Prime Capital Partners Life Sciences Fund IX LP | Current | |
| Owner (10%) | ABV 9 Lux VI, S.C.Sp. | Current | |
| Owner (10%) | RA Capital Healthcare Fund, L.P. | Current | |
| Owner (5%) | Novartis Bioventures AG | Current | |
| Owner (50%) | Novo Holdings A/S | ||
| Owner (25%) | Demetrios Thomas Braddock | ||
| Owner (33%) | Novo Holdings A/S | ||
| Owner (5%) | Demetrios Thomas Braddock | ||
| Owner (10%) | F-Prime Capital Partners Life Sciences Fund IX LP | ||
| Owner (10%) | ABV 9 Lux VI, S.C.Sp. | ||
| Owner (10%) | RA Capital Healthcare Fund, L.P. | ||
| Owner (5%) | Novartis Bioventures AG | ||
| Auditor | EY Godkendt Revisionspartnerselskab | Current | |
| Founder | Novo Holdings A/S | Current |
The CEOs' other companies
Søren Sylvester Skjærbæk – 12 other companies, of which 1 bankrupt
- LEDBANNER A/S Bankrupt 16 Sep 2010
- ACTAS A/S Active
- Akylox Therapeutics ApS Active
- BIOMEDICOS A/S Compulsorily dissolved
- HyperBio Therapeutics ApS Opløst
- JOMS ApS Active
- Life Science Legal ApS Active
- NSEXPLORER A/S Opløst
- NSGENE A/S Opløst
- Orbis Medicines ApS Active
- SOJA ApS Opløst
- UNIKUM Therapeutics ApS Active
Jørgen Søberg Petersen – 10 other companies
- ACESION PHARMA ApS Active
- Allarity Therapeutics A/S Opløst
- Allarity Therapeutics Europe ApS Active
- Antag Therapeutics ApS Active
- BLUE Healthcare Investments ApS Opløst
- Breye Therapeutics ApS Active
- Hemab ApS Active
- INAGEN ApS Opløst
- ZEALAND PHARMA A/S Active
- mAbSolution IVS Opløst
Address history (1 moves)
| c/o Symbion, Fruebjergvej 3, 2100 København Ø | |
| Nordre Fasanvej 215, 2000 Frederiksberg |
Other companies at the same address
- A DIMENSION GROUP A/S Bankrupt
- A-SYNTESE BIOTECH ApS Bankrupt
- ABSTRACTION ApS Bankrupt
- ADURA ApS Bankrupt
- AFVIKLINGSSELSKABET AF 8.2.1999 A/S Bankrupt
- ALLEGENETICS DIAGNOSTICS LABORATORY ApS Bankrupt
- ANSARI GROUP S.M.B.A. Bankrupt
- AQUALIFE A/S Bankrupt
- AREA NETWORKS ApS Bankrupt
- ASD Group Denmark ApS Bankrupt
- Afsluttet Projektselskab BLN ApS Bankrupt
- Andersen & Andersen IVS Bankrupt
- Andersentraveller ApS Bankrupt
- ApS VICTORIA STREET KOMPLEMENTAR Bankrupt
- Autocycle International ApS Bankrupt
- BB Ejendomme 2015 IVS Bankrupt
- BB Jyllands investering IVS Bankrupt
- BB Jyllands projekt IVS Bankrupt
- BINCORE GROUP A/S Bankrupt
- BINCORE INDUSTRIES A/S Bankrupt
- BLUSENSE DIAGNOSTICS APS Bankrupt
- BRUUNS INVEST ApS Bankrupt
- BRUUNS REVISION ApS Bankrupt
- BUILD ApS Bankrupt
- Baunsgaard Technologies ApS Bankrupt
Similar companies in København
- CARLSBERG A/S København V
- CuraVision ApS København V
- Launch Bioindustries ApS København Ø
- Vitibiotech ApS København N
- Pyovita ApS Hellerup
- ArcanaBio ApS København N
- OvartiX ApS København N
- Keystone Consulting ApS København SV
- KPL ApS København N
- Alveus Therapeutics ApS København K
- Cambiotics ApS København N
- Polyceutix ApS København N
Questions and answers about RheumaLogics ApS
Has RheumaLogics ApS gone bankrupt?
No, RheumaLogics ApS is not registered as bankrupt in the CVR register. Its status is: active.
What is the bankruptcy risk of RheumaLogics ApS?
Our model estimates a bankruptcy risk of 1.6% over the next 12 months (medium risk), which is 1.1 times the average for Danish companies.
Who is the CEO of RheumaLogics ApS?
Søren Sylvester Skjærbæk is the CEO of RheumaLogics ApS.
Who is the auditor of RheumaLogics ApS?
RheumaLogics ApS most recently used EY Godkendt Revisionspartnerselskab.
When was RheumaLogics ApS founded?
RheumaLogics ApS was founded on 5 December 2024.
What is the equity of RheumaLogics ApS?
Equity was DKK 22.4m according to the annual report for the period ending 31 December 2025.
Source: the CVR register and annual reports published by the Danish Business Authority. The information is updated continuously.